ViaCyte, a regenerative medicine company long backed by CIRM, announced a partnership with CRISPR Therapeutics to increase the number of people with Type 1 Diabetes (T1D) who could benefit from their PEC-Direct therapeutic implant. Last year, CIRM granted ViaCyte $20 million to facilitate development of PEC-Direct, a device that both transplants pancreatic progenitor stem … Continue reading New partnership to make CIRM supported treatment for type 1 diabetes even better
Paul Laikind
CIRM Board targets diabetes and kidney disease with big stem cell research awards
A recent study estimated there may be more than 500 million people worldwide who have diabetes. That’s an astounding figure and makes diabetes one of the largest chronic disease epidemics in human history. One of the most serious consequences of untreated or uncontrolled diabetes is kidney damage. That can lead to fatigue, weakness, confusion, kidney … Continue reading CIRM Board targets diabetes and kidney disease with big stem cell research awards
The best scientists always want to know more
Some years ago I was in the Wren Library at Trinity College, Cambridge in England when I noticed a display case with a cloth over it. Being a naturally curious person, downright nosy in fact, I lifted the cloth. In the display case was a first edition of Sir Isaac Newton’s Principia Mathematica and in … Continue reading The best scientists always want to know more
Moving one step closer to a therapy for type 1 diabetes
When I was a medical journalist one word I always shied away from was “breakthrough”. There are few true breakthroughs in medicine. Usually any advance is the result of years and years of work. That’s why good science takes time; it takes hundreds of small steps to make a giant leap forward. Today we took … Continue reading Moving one step closer to a therapy for type 1 diabetes
The Stem Cellar 